ResMed Inc. (NYSE:RMD) Shares Bought by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. raised its holdings in ResMed Inc. (NYSE:RMD) by 5.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,818 shares of the medical equipment provider’s stock after purchasing an additional 255 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in ResMed were worth $1,102,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of RMD. Chicago Partners Investment Group LLC acquired a new stake in shares of ResMed in the fourth quarter worth approximately $340,000. Cibc World Market Inc. boosted its stake in ResMed by 51.9% during the fourth quarter. Cibc World Market Inc. now owns 53,181 shares of the medical equipment provider’s stock worth $12,162,000 after buying an additional 18,159 shares during the last quarter. Mediolanum International Funds Ltd boosted its stake in ResMed by 178.9% during the fourth quarter. Mediolanum International Funds Ltd now owns 31,012 shares of the medical equipment provider’s stock worth $7,100,000 after buying an additional 19,893 shares during the last quarter. Synergy Asset Management LLC acquired a new position in ResMed during the fourth quarter worth $129,000. Finally, Swedbank AB boosted its stake in ResMed by 0.8% during the fourth quarter. Swedbank AB now owns 72,891 shares of the medical equipment provider’s stock worth $16,669,000 after buying an additional 601 shares during the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RMD. Stifel Nicolaus began coverage on ResMed in a research note on Friday, December 13th. They set a “hold” rating and a $250.00 price objective on the stock. Robert W. Baird boosted their price objective on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. KeyCorp lifted their target price on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research report on Friday. Piper Sandler lifted their target price on ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a research report on Friday. Finally, StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $244.73.

Insiders Place Their Bets

In other ResMed news, insider Justin Leong sold 6,160 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the sale, the insider now owns 21,718 shares in the company, valued at $5,279,428.62. This represents a 22.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,030 shares of company stock worth $2,702,687 in the last quarter. 0.71% of the stock is owned by company insiders.

ResMed Price Performance

RMD stock opened at $241.15 on Tuesday. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $35.40 billion, a PE ratio of 28.47, a P/E/G ratio of 1.69 and a beta of 0.70. ResMed Inc. has a 12-month low of $170.56 and a 12-month high of $263.05. The business’s fifty day moving average price is $240.17 and its 200 day moving average price is $236.63.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, sell-side analysts anticipate that ResMed Inc. will post 9.41 EPS for the current year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.88%. ResMed’s dividend payout ratio (DPR) is 25.03%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.